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A B S T R A C T
It is now established that cholesterol oxidation products (oxysterols) are involved in several events underlying
Alzheimer's disease (AD) pathogenesis. Of note, certain oxysterols cause neuron dysfunction and degeneration
but, recently, some of them have been shown also to have neuroprotective eﬀects. The present study, which
aimed to understand the potential eﬀects of 24-hydroxycholesterol (24-OH) against the intraneuronal accu-
mulation of hyperphosphorylated tau protein, stressed these latter eﬀects. A beneﬁcial eﬀect of 24-OH was
demonstrated in SK-N-BE neuroblastoma cells, and is due to its ability to modulate the deacetylase sirtuin 1
(SIRT1), which contributes to preventing the neurotoxic accumulation of the hyperphosphorylated tau protein.
Unlike 24-OH, 7-ketocholesterol (7-K) did not modulate the SIRT1-dependent neuroprotective pathway. To
conﬁrm the neuroprotective role of 24-OH, in vivo experiments were run on mice that express human tau
without spontaneously developing tau pathology (hTau mice), by means of the intracerebroventricular injection
of 24-OH. 24-OH, unlike 7-K, was found to completely prevent the hyperphosphorylation of tau induced by
amyloid β monomers. These data highlight the importance of preventing the loss of 24-OH in the brain, and of
maintaining high levels of the enzyme SIRT1, in order to counteract neurodegeneration.
Graphical abstract: A hypothetical scheme of the molecular mechanisms underlying the eﬀects of 24-OH on
hyperphosphorylated tau accumulation.
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1. Introduction
Alzheimer's disease (AD) is one of the biggest health and social care
challenges world-wide. The diﬃculty of early diagnosis of AD, and the
lack of eﬀective therapies, provide incentives for the development of
new strategies to prevent or slow this disabling disease.
In AD, hyperphosphorylated tau and Aβ accumulate, respectively
generating intraneuronal neuroﬁbrillary tangles (NFT) and extra-
cellular senile plaques. Regarding the formation of these two lesions,
ﬁndings concerning which comes ﬁrst are discordant; however,
growing evidence recognizes the very early onset of tau pathology
[1,2].
In normal conditions, tau is involved in microtubule assembly and
stability, and in neuronal survival; under pathological conditions, tau
undergoes excessive phosphorylation and acetylation, resulting in ag-
gregation in toxic insoluble oligomers that destabilize the microtubules.
In particular, the hyperphosphorylation of tau reduces its binding to the
microtubules, whereas tau hyperacetylation inhibits ubiquitin-medi-
ated proteolysis of phosphorylated tau, thereby promoting its self-ag-
gregation. Consequently, microtubules depolymerize and NFT accu-
mulate inside neurons leading to neurodegeneration [3].
In the last few years, a close link between brain cholesterol dysho-
meostasis and AD has been recognized, but it remains unclear at what
stage the cholesterol biosynthetic pathway is perturbed, and how this
contributes to AD pathogenesis. Thanks to a large body of research, it is
now believed that one of the main triggers in AD is oxidized cholesterol
in the form of oxysterols [4,5].
Cholesterol homeostasis in the normal brain is tightly regulated:
cholesterol is synthetized de novo by astrocytes and then loaded with
apolipoprotein E which drives it to neurons. Once internalized by
neurons, excess cholesterol is oxidized into 24-hydroxycholesterol (24-
OH) by the enzyme CYP46A1 or into 27-hydroxycholesterol (27-OH) by
the enzyme CYP27A1. Of note, 24-OH is one of the main oxysterols
most closely involved in AD pathogenesis since its levels are markedly
decreased, because of the loss of neurons expressing CYP46A1 [6].
Indeed, previous research by the present authors on the frontal and
occipital cortex of AD patients, classiﬁed by the Braak staging system of
neuroﬁbrillary pathology, have clariﬁed the association between the
concentrations of oxysterols in the brain and progression of the disease
[7]. These data underline the signiﬁcant reduction of 24-OH levels,
unlike the other oxysterols, in the brain during the progression of AD,
and it is likely that its loss is a factor in accelerating development of the
disease. Of note, it was observed that expression levels of the gene
coding for the enzyme responsible for the formation of 24-OH,
CYP46A1, decreased in parallel with its loss. Conversely, other oxy-
sterols signiﬁcantly increased, including 27-OH, an oxysterol of enzy-
matic origin like 24-OH, and some oxysterols deriving from cholesterol
autooxidation, such as 7-ketocholesterol (7-K), 25-hydroxycholesterol,
7α- and 7β-hydroxycholesterol, α- and β-epoxycholesterol, 4α- and 4β-
hydroxycholesterol [7]. These observations are in agreement with other
studies that correlate speciﬁc oxysterols with disease state [8,9].
The idea is now emerging that certain oxysterols, accumulating in
the brain during AD, can act as friends and/or foes: it has clearly been
observed that they cause neuron dysfunction and degeneration, con-
tributing to neuroinﬂammation and amyloidogenesis, but, conversely,
some oxysterols can also be neuroprotective. The underlying molecular
mechanisms, however, remain to be fully elucidated, in particular
concerning the beneﬁcial eﬀects.
AD is characterized by both amyloid and tau pathology [10]. The
link between altered cholesterol metabolism and amyloid beta (Aβ)
accumulation has been extensively investigated [11–14], but its re-
lationship with tau pathology is currently almost entirely unknown,
with very few exceptions [15–17].
This paper aimed to compare the eﬀects of 24-OH and 7-K, on tau
phosphorylation, a ﬁeld hitherto completely unexplored.
Intraneuronal accumulation of NFT made of hyperphosphorylated
tau protein is directly correlated with cognitive decline in AD and other
primary tauopathies, making it crucial to ﬁnd neuroprotective path-
ways that might prevent or reduce the hyperphosphorylation of tau. In
particular, the focus here was on the sirtuin 1 (SIRT1)-dependent
neuroprotective pathway, because it appears to display protective ef-
fects against AD progression, and it might be closely involved in the
neuroﬁbrillary pathology. The deacetylase SIRT1 is considered pro-
survival, because of its several beneﬁcial eﬀects, including the ability to
inhibit NFT and Aβ plaque accumulation [18].
Interestingly, the present group recently demonstrated that ex-
pression of SIRT1 in the brain drastically decreases with the progression
of AD, suggesting that, in parallel with the loss of 24-OH, its reduction
might play a key role in AD pathology. Moreover, it was observed that,
in the AD-aﬀected brain, the accumulation of hyperphosphorylated tau
co-occurs with the reduction of SIRT1 activity. It also appears clear that
SIRT1 reduction correlates with neuroinﬂammation in AD. In parti-
cular, elevated inﬂammatory molecule levels have been detected in the
brain of AD patients in the earlier phases of AD, precisely when SIRT1
levels begin to shrink [7,19,20].
To investigate whether the reduction of 24-OH in the AD brain
might be responsible for the concurrent reduction of SIRT1 and the
consequent tau hyperphosphorylation, the ability of 24-OH to modulate
the SIRT1-dependent neuroprotective pathway was analyzed in SK-N-
BE neuroblastoma cells. It was shown that 24-OH, unlike 7-K, activates
the SIRT1-dependent neuroprotective pathway, by inducing the in-
tracellular generation of reactive oxygen species (ROS). Consequently,
24-OH favors tau deacetylation and prevents intracellular accumulation
of hyperphosphorylated tau.
It is worthy of note that the strong neuroprotective action of 24-OH
was also conﬁrmed, in vivo, in mice expressing human tau (hTau mice)
that produce tau aggregates after Aβ monomer administration. The
hTau mice were subjected to an intracerebroventricular (ICV) injection
of 24-OH which has been shown to be eﬀective against tau hyperpho-
sphorylation induced by Aβ.
For the ﬁrst time, the results demonstrate an important role for 24-
OH in reducing hyperphosphorylated tau accumulation, a sort of “silver
lining” for this oxysterol, which thus far has been observed to exert
mainly negative eﬀects.
2. Materials and methods
2.1. Cell culture and treatments
SK-N-BE neuroblastoma cells were maintained in RPMI 1640
medium supplemented with 2mM glutamine, 10% FBS, 1% non-es-
sential aminoacids and 1% antibiotic mixture at 37 °C with 5% CO2.
Cells were treated with 1 μM 24-OH (Avanti Polar Lipids Inc., Alabaster,
AL, USA) or with 1 µM 7-K (Steraloids, Newport, RI, USA), both dis-
solved in ethanol. In some experiments, cells were pretreated with
300 μM apocynin 1 h before oxysterol treatment, or were cotreated with
2.5 μM rotenone.
2.2. Mice and ICV injections
Mice expressing human tau, hTau mice (Mapt tm1(EGFP)KltTg(MAPT)
8cPdav/J; #004808, The Jackson Laboratory, Bar Harbor, ME, USA),
were crossed with tau knock-out (KO) mice (Mapt tm1(EGFP)Klt/J;
#004779, Jackson Laboratory), to obtain pregnant females carrying
hTau fetuses [21]. The mice were genotyped by PCR assay as described
by Manassero and colleagues [22]. They were maintained on a Swiss
Webster/129/SvJae/C57BL/6 background [21], and kept on a 12 h
light/dark cycle with food and water available ad libitum.
All experimental procedures on live animals were performed under
the supervision of a licensed veterinarian, in agreement with: i)
European Communities Council Directive (November 24, 1986; 86/
609/EEC); ii) Italian Ministry of Health and University of Turin's
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institutional guidelines on animal welfare (DL 116/92 on Care and
Protection of living animals undergoing experimental or other scientiﬁc
procedures; authorization No. 17/2010-B, June 30, 2010); iii) the ad
hoc Ethical Committee of the University of Turin (http://www.unito.it/
unitoWAR/page/istituzionale/ricerca1/Ricerca_comitato1).
For the experimental procedures, 2 month-old male hTau mice were
used; under isoﬂurane O2/N2O anesthesia, the mice (n= 30) were ICV
injected with 1 μM 24-OH or 1 μM 7-K for 4 days, and then with 0.2 μM
Aβ1–42 monomers (AnaSpec, Seraing, Belgium) or saline (control mice)
for 3 h. The lyophilized synthetic Aβ peptides were dissolved in 1%
NH4OH to get a clear solution and stored at −20 °C in aliquots.
Monomeric preparations were brought to 0.2 μM (ﬁnal concentration)
with sterile double distilled water, centrifuged at 10,000 g for 10min to
remove possible aggregates. The quality of Aβ preparations was routi-
nely controlled using atomic force microscopy [22]. Both 24-OH and 7-
K were dissolved in ethanol at the ﬁnal concentration of 1 μM for ICV
injection. Coordinates used for injection were: anteroposterior,
−0.5mm; lateral, 1.2 mm relative to bregma and dorsoventral, 1.7 mm
from the dural surface. The method was validated by injecting one
mouse with Trypan blue (1 µL).
2.3. Small interfering RNA (siRNA) transfection
SIRT1 siRNA was used for transient gene knockdown study (Life
Technologies, Thermo Fisher Scientiﬁc, Monza, Italy). Transfection of
SIRT1 siRNA was performed following the manufacturer's instructions.
Brieﬂy, 25 µL of 100 nM siRNA were mixed with 25 µL of transfection
reagent solution containing 1.5 µL of trasfection reagent
(Lipofectamine® RNAiMAX Reagent, Life Technologies) and left for
10min in RPMI medium with 1% FBS and without antibiotics. After
48 h of reverse transfection, the cells (6× 104/500 µL) were incubated
with 1 μM 24-OH for 15 h. Total RNA was isolated from the cells and
used for quantitative RT-PCR as described below. The transfection ef-
ﬁciency, validated by quantitative RT-PCR, was approximately 77%.
Total protein extract was obtained from the cells following the protocol
described below.
2.4. RNA extraction and cDNA synthesis
Total RNA was extracted using TRIzol Reagent (Life Technologies)
following the manufacturer's instructions. RNA was dissolved in RNase-
free water fortiﬁed with RNase inhibitors (RNaseSUPERase-In; Life
Technologies). The amount and purity (A260/A280 ratio) of the ex-
tracted RNA were assessed spectrophotometrically. cDNA was synthe-
sized by reverse transcription from 2 μg RNA with a commercial kit and
random primers (High-Capacity cDNA Reverse Transcription Kit; Life
Technologies) following the manufacturer's instructions.
2.5. Real time RT-PCR
Singleplex real-time RT-PCR was performed on 30 ng cDNA using
TaqMan Gene Expression Assay kits prepared for human SIRT1 and β2-
microglobulin, TaqMan Fast Universal PCR Master Mix, and 7500 Fast
Real-Time PCR System (Life Technologies). The oligonucleotide se-
quences are not revealed by the manufacturer because of proprietary
interests. The cycling parameters were as described by Gamba and
colleagues [11]. The fractional cycle number (Ct) at which ﬂuorescence
passes the threshold in the ampliﬁcation plot of ﬂuorescence signal
versus cycle number was determined for each gene considered. The
results were then normalized to the expression of β2-microglobulin.
Relative quantiﬁcation of target gene expression was achieved with a
mathematical method [23].
2.6. Protein extraction and Western blotting
Cells were lysed in ice-cold lysing buﬀer (1 mL PBS fortiﬁed with
10 µL Triton X-100, 10 µL SDS 10%, 5 µL DTT 1M, 6 µL PMSF 0.1%, and
10 µL aprotinin) (30min), sonicated on ice, and then centrifugated at
17,860 g (15min). Fresh frozen brains were mechanically homogenized
in ice-cold buﬀer (25mM Tris-HCl pH 7.4, 150mM NaCl, 1 mM EGTA,
1mM EDTA, 1mM PMSF, phosphatase and protease inhibitors) and
then centrifuged at 10,000 g (15min) to isolate soluble proteins.
To analyze the protein levels, 50 µg (cell lysates) or 20 µg (brain
lysates) of total proteins were separated by electrophoresis in 8% de-
naturing SDS/polyacrylamide gel, then transferred to Amersham
Hybond PVDF membrane (GE Healthcare Europe, Milan, Italy). After
saturation of non-speciﬁc binding sites with 5% non-fat milk in Tris-
buﬀered saline 1x-Tween 20 0.05% for 1 h, the membrane was im-
munoblotted overnight at 4 °C with the primary antibodies against
SIRT1 (1:1000) (Cell Signaling Technology, Denver, CO, USA or Merk-
Millipore, Darmstadt, Germany), tau (1:750), phospho-tau (1:400)
(Santa Cruz Biotechnology Inc., Denver, CO, USA), and acetyl-tau
(1:200) (AnaSpec), AT8 (1:500) (Innogenetics, Alpharetta, GA, USA) or
tau5 (1:500) (Merk-Millipore). The membranes were stripped and re-
immunoblotted with anti-α-tubulin (1:1000) (Cell Signaling
Technology) or with anti-β-actin (1:5000) primary antibody (Sigma-
Aldrich, St. Louis, MO, USA).
The immunoreactive bands were visualized through enhanced
chemiluminescence using Clarity Western ECL Substrate (Bio-Rad
Laboratories Inc.) following the manufacturer's protocol. The bands
were quantiﬁed by densitometric analysis using Image J 1.43 software.
The results were evaluated as relative units determined by normal-
ization of the density of each band to that of the corresponding α-tu-
bulin or β-actin protein band.
2.7. Measurement of intracellular ROS
The production of ROS, principally superoxide anion (O2.-), was
detected by dihydroethidium (DHE) ﬂuorescence staining (Sigma-
Aldrich). After treatment, the cells were washed and resuspended with
RPMI-1640 medium (fortiﬁed with 2% FBS) and incubated for 30min
in the dark with 5 μM DHE at 37 °C. Fluorescence was immediately
detected with a confocal laser microscope (Zeiss LSM 510; Carl Zeiss
S.p.A., Arese, Milan, Italy) setting the exciting laser band to 543 nm,
and using a 560–615 nm band-pass emission ﬁlter (plan neoﬂuar lens
40×/0.75). All images were processed using LSM 510 Image Examiner
software (Carl Zeiss S.p.A.).
2.8. Analysis of SIRT1 and phospho-tau by immunoﬂuorescence
Cells were grown on glass slides and, after treatments, specimens
were ﬁxed in 4% formalin for 15min and then washed with 0.1 M PBS.
After blocking nonspeciﬁc binding sites with 0.1 M PBS containing 5%
goat serum, 3% BSA, and 0.3% Tween 20, for 30min, slides were in-
cubated in the presence of primary antibodies against SIRT1 (1:150) or
against phospho-tau (1:150) (Santa Cruz Biotechnology Inc.) for 1.5 h,
and then with speciﬁc secondary antibodies (1:300) conjugated with
ﬂuorescein isothiocyanate (FITC) ﬂuorochrome (Alexa Fluor, Molecular
Probes, Life Technologies) for 1 h. Slides, mounted with Fluoroshield
(Sigma-Aldrich), were observed through a LSM 510 confocal laser mi-
croscope (Carl Zeiss S.p.A.) (488 nm exciting laser band and emission
passing through a long-pass 505–550 ﬁlter, lens 40×/0.75). The
images were processed using LSM 510 Image Examiner software (Carl
Zeiss S.p.A.).
2.9. Statistical analysis
All values are expressed as means ± SD. Data were analyzed sta-
tistically using one-way ANOVA with Bonferroni's post test for multiple
comparisons. Diﬀerences at P < 0.05 were considered statistically
signiﬁcant. Calculations were performed using GRAPHPAD INSTAT3
software (GraphPad Software Inc., San Diego, CA, USA).
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3. Results
3.1. 24-OH, unlike 7-K, upregulates both expression and synthesis of SIRT1
With the aim of determining whether the oxysterols 24-OH and 7-K
are able to modulate the SIRT1-dependent neuroprotective pathway,
the expression and synthesis of SIRT1 were measured after treatment of
neuroblastoma SK-N-BE cells either with 24-OH (Fig. 1) or with 7-K
(Fig. 2), both at the physiopathological concentration of 1 µM.
SIRT1 gene expression was found to be signiﬁcantly upregulated
only by 24-OH, the eﬀect being evident after 10min and continuing to
2 h, with a maximum at 1 h; after 2 h cell treatment with 24-OH there
was a progressive reduction in SIRT1 expression levels, until control
levels were reached (6 h) (Fig. 1A). Conversely, 7-K did not induce
SIRT1 expression at any time (Fig. 2A).
As regards SIRT1 protein levels, it emerged that 24-OH induced its
synthesis after 3 h cell treatment, as demonstrated by Western blotting
(Fig. 1B) and immunocytochemistry (Fig. 1C). Again, 7-K did not
modulate protein levels of SIRT1 in neurons (Fig. 2B and C).
3.2. 24-OH, unlike 7-K, reduces tau acetylation, thus preventing
hyperphosphorylated tau accumulation
To check whether modulation of the expression and synthesis of the
deacetylase SIRT1 by 24-OH (as shown in Fig. 1) is actually followed by
its activation, the levels of acetylated tau (acetyl-tau) were analyzed by
Western blotting. Levels of total and phosphorylated tau (phospho-tau)
were also measured, in order to verify the oxysterol's eﬀect in mod-
ulating NFT formation.
SK-N-BE cells were treated with 1 µM 24-OH for times ranging from
6 h to 24 h. 24-OH signiﬁcantly reduced levels of both tau acetylation
and tau phosphorylation (Fig. 3A). As regards acetyl-tau, it was sig-
niﬁcantly reduced after 6 and 15 h, and the consequent tau phosphor-
ylation levels were also markedly inhibited after 6 and 15 h. Both
acetyl- and phospho-tau were measured by normalizing their levels to
α-tubulin content. Interestingly, 24-OH was also found to reduce tau
protein levels after 6 and 15 h (Fig. 3A). This reduction is presumably
due to tau deacetylation, which is known to favor tau proteasomal
degradation [3]; this hypothesis is clearly supported by the evidence of
the progressive reduction until 15 h of phospho-tau/tau ratio (Fig. 3B).
The same experiments were carried out on cells treated with 1 µM 7-
K (Fig. 4). Of note, 7-K aﬀected neither tau acetylation, nor tau
Fig. 1. Eﬀect of 24-OH on SIRT1 expression and synthesis in SK-N-BE cells. (A)
Gene expression was quantiﬁed in cells treated with 24-OH. Data, normalized
to β2-microglobulin, are expressed as mean values ± SD of 4 experiments.
*P < 0.05, **P < 0.01, and ***P < 0.001 vs control. (B) SIRT1 protein levels
were analyzed in cells treated with 24-OH. The blot shown is representative of 3
experiments. The histograms represent mean values ± SD of 3 experiments.
SIRT1 densitometric measurements were normalized against the corresponding
α-tubulin levels and expressed as percentage of control value. *P < 0.05 vs
control. (C) After cell treatment with 24-OH, SIRT1 protein levels were detected
by confocal laser microscopy. The images are representative of 3 experiments.
Fig. 2. Eﬀect of 7-K on SIRT1 expression and synthesis in SK-N-BE cells. (A)
Gene expression was quantiﬁed in cells treated with 7-K. Data, normalized to
β2-microglobulin, are expressed as mean values ± SD of 4 experiments. (B)
SIRT1 protein levels were analyzed in cells treated with 7-K. The blot shown is
representative of 3 experiments. The histograms represent mean values ± SD
of 3 experiments. SIRT1 densitometric measurements were normalized against
the corresponding α-tubulin levels and expressed as percentage of control
value. (C) After cell treatment with 7-K, SIRT1 protein levels were detected by
confocal laser microscopy. The images are representative of 3 experiments.
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phosphorylation, nor total tau, conﬁrming that this oxysterol is not able
to activate the SIRT1-dependent pathway (Fig. 4A). Interestingly, it
even appears to have an opposing eﬀect: it causes a slight increase,
evident although not signiﬁcant, of both acetyl- and phospho-tau levels.
Unlike 24-OH cell treatments, 7-K did not aﬀect the ratio between
phospho-tau and total tau (Fig. 4B).
3.3. 24-OH increases ROS steady-state levels in SK-N-BE cells
The incubation of SK-N-BE cells with 1 µM 24-OH induced, already
after 1 h, a marked increase of ROS levels, as observed in DHE-stained
cells. Conversely, incubation of the cells with 1 µM 7-K caused no ROS
increase over control levels (Fig. 5A). Some evidence points to the
ability of oxysterols to upregulate NADPH oxidase and to impair mi-
tochondrial membrane potential, thus producing high levels of in-
tracellular ROS [24–26]. On this basis, the involvement of NADPH
oxidase and mitochondrial membrane potential derangement in the
observed ROS production was veriﬁed. Neurons were treated with 24-
OH for 1 h, in the presence or absence of 300 μM apocynin or 2.5 μM
rotenone, speciﬁc inhibitors of NADPH oxidase and mitochondrial
electron transport chain, respectively. Of note, apocynin and rotenone
prevented ROS production (Fig. 5A).
In agreement with these data, NADPH oxidase activation and mi-
tochondrial derangement were shown to be sources of ROS in 24-OH-
treated cells (data not shown).
3.4. 24-OH prevents hyperphosphorylated tau accumulation through the
ROS/SIRT1-dependent neuroprotective pathway
The involvement of ROS production in SIRT1-dependent inhibition
of phospho-tau intraneuronal accumulation was conﬁrmed. Cells were
pretreated (1 h) with apocynin (300 µM), or cotreated with rotenone
(2.5 µM), and then with 24-OH (1 µM) for 3 h (Fig. 5B) or for 15 h
(Fig. 5C). The increase of SIRT1 levels in neuroblastoma cells incubated
with 24-OH was further conﬁrmed by immunocytochemistry after 3 h
cell treatment; this eﬀect was completely prevented by the adminis-
tration of the ROS inhibitors, either of apocynin or rotenone (Fig. 5B).
As a consequence of SIRT1 positive modulation, the inhibition of tau
phosphorylation was again demonstrated after 15 h cell treatment, and,
also in this case, ROS production was shown to be a key step, since both
inhibitors (apocynin and rotenone) counteracted the protective eﬀect of
24-OH (Fig. 5C). In particular, in both experiments it was noted that 24-
OH acts by inducing the activation of NADPH oxidase and
Fig. 3. Eﬀect of 24-OH on the levels of acetylated, phosphorylated, and total
tau in SK-N-BE cells. (A) Acetyl-tau, phospho-tau, and total tau levels were
analyzed in cells treated with 24-OH. Each blot shown is representative of 3
experiments. The histograms represent mean values ± SD of 3 experiments.
Densitometric measurements were normalized against the corresponding α-
tubulin levels and expressed as percentage of control value. *P < 0.05 and
***P < 0.001 vs control. (B) Phospho-tau/tau ratio derived from densitometric
measurements. *P < 0.05 and **P < 0.01 vs control.
Fig. 4. Eﬀect of 7-K on the levels of acetylated, phosphorylated, and total tau in
SK-N-BE cells. (A) Acetyl-tau, phospho-tau, and total tau levels were analyzed
in cells treated with 7-K. Each blot shown is representative of 3 experiments.
The histograms represent mean values ± SD of 3 experiments. Densitometric
measurements were normalized against the corresponding α-tubulin levels and
expressed as percentage of control value. (B) Phospho-tau/tau ratio derived
from densitometric measurements.
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Fig. 5. Eﬀect of 24-OH and 7-K on ROS production and modulation of SIRT1 and phospho-tau levels by 24-OH in SK-N-BE cells. (A) Cells were treated with 24-OH or
7-K. The intracellular generation of ROS was monitored by DHE ﬂuorescence staining. (B) The levels of SIRT1 and (C) phospho-tau were observed in cells incubated
with 24-OH. Some cells were incubated with apocynin or with rotenone, and then treated with 24-OH. ROS, SIRT1, and phospho-tau levels were detected by confocal
laser microscopy. The images are representative of 3 experiments. (D) Phospho-tau levels were analyzed in cells transfected with a speciﬁc SIRT1 siRNA and then
incubated with 24-OH for 15 h. The blot is representative of 3 experiments and the histograms represent mean values ± SD of 3 experiments. Phospho-tau den-
sitometric measurements were normalized against the corresponding α-tubulin levels and expressed as percentage of control value. ** p < 0.01 vs control; ##
p < 0.01 vs 24-OH.
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mitochondrial derangement, thus leading to the release of ROS, which
act as signal modulators, inducing the upregulation of the SIRT1-de-
pendent pathway.
It was further demonstrated that the 24-OH-dependent neuropro-
tective eﬀect, represented by the inhibition of tau hyperpho-
sphorylation, actually depends on SIRT1 activation; when SIRT1 is si-
lenced, tau phosphorylation is no longer prevented (Fig. 5D).
3.5. In vivo administration of 24-OH, but not of 7-K, prevents
hyperphosphorylated tau accumulation in hTau mice by SIRT1 upregulation
To determine whether 24-OH or 7-K induce tau phosphorylation in
hTau mice, the levels of tau phosphorylation were measured using the
AT8 antibody (Fig. 6). hTau mice injected ICV with monomeric pre-
parations of Aβ1–42, which has been found to signiﬁcantly increase tau
phosphorylation [22], were used as positive controls. As expected, 3 h
after the Aβ1–42 monomer injection, the hyperphosphorylation of tau
signiﬁcantly increased. Pretreatment with 24-OH (4 days) completely
prevented the hyperphosphorylation of tau, whereas 7-K alone or in
combination with Aβ1–42 mediated a signiﬁcant increase of tau phos-
phorylation. The total tau levels were also evaluated (Fig. 6), and it
emerged that Aβ1–42 signiﬁcantly increased the total levels of tau.
Pretreatment with 24-OH signiﬁcantly but not completely decreased
total tau levels, while 7-K alone or in combination with Aβ1–42 sig-
niﬁcantly increased them. The eﬀect of 24-OH appears to be due to its
capacity to increase SIRT1 levels in the brain of hTau mice, compared
to hTau mice injected with Aβ1–42 or with 7-K (Fig. 6).
4. Discussion
Despite the many studies on the pathogenesis of AD, the exact se-
quence of events leading to neurodegeneration in the brain has not yet
been fully clariﬁed; however, in recent years increasing experimental
evidence points to disordered cholesterol metabolism in the brain as
one of the main drivers of AD development [4,5].
Many studies have focused on understanding the molecular me-
chanisms whereby cholesterol oxidation contributes to AD develop-
ment, and it has emerged that the behavior of oxysterols is without
doubt peculiar: they are double-edged compounds, showing both det-
rimental and beneﬁcial properties at the same time. In this connection,
it has been demonstrated that the oxysterols are capable of triggering
both death and survival signals within cells, depending on the experi-
mental model [26–30].
The role of 24-OH in AD in some contexts is controversial and still
debated. The eﬀects exerted by 24-OH appear to depend on its con-
centration: high concentrations (25–50 µM) are toxic to neuroblastoma
SH-SY5Y cells [31] while conversely pretreatment with low sub-lethal
concentrations of 24-OH (1–10 µM), within the range observed in
human brain, induces an adaptive response via activation of liver x
receptor, and counteracts the 7-K-dependent cytotoxicity [32]. In an-
other experimental model, it has been shown that 24-OH (1 µM) is not
neurotoxic per se, while it markedly potentiates both the apoptotic and
the necrogenic eﬀects exerted by Aβ1–42 peptide on diﬀerent neuronal
cells. This eﬀect was due to 24-OH's ability to enhance the binding of
Aβ to neurons, and thus its intracellular accumulation, by amplifying
the availability of a multireceptor complex (CD36/β1-integrin/CD47)
on the cell membranes [11,33]. However, opinions still diﬀer about the
involvement of 24-OH in amyloid precursor protein (APP) processing
and, consequently, in Aβ production. It has been shown that, in neu-
ronal SK-N-BE cells, 1 µM 24-OH enhances the expression and activity
of β-secretase, the main enzyme involved in the APP amyloidogenic
pathway, and consequently leads to increased Aβ generation and ac-
cumulation [12]. Conversely, it has been reported that 24-OH
(5–10 µM) can inhibit Aβ plaque formation by favoring the non-amy-
loidogenic APP pathway [34,35]. Another study suggests that 24-OH
(1–10 µM) is able to reduce Aβ production by downregulating the in-
tracellular APP traﬃcking [14]. Of note, 24-OH is a selective positive
allosteric modulator of N-methyl-D-aspartate receptors (NMDARs) that
Fig. 6. 24-OH protects against phosphorylated and total
tau accumulation induced by Aβ1–42 in mouse brain. hTau
mice were ICV injected with 24-OH or 7-K for 4 days, and
then with Aβ1–42 or saline (control) for 3 h. Representative
blots of brain extracts, using SIRT1, AT8 or Tau5.
Densitometric measurements were normalized against the
corresponding β-actin levels and expressed mean
values ± SD, n= 5 each group. **p < 0.01 and
***p < 0.001 vs control; #p < 0.05 and ###
p < 0.001 vs Aβ1–42.
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are critical to the regulation of excitatory synaptic function. 24-OH
(2 µM) potentiates NMDAR-mediated responses and restore cognitive
deﬁcit in rodents treated with NMDAR channel blockers [36].
The role of 7-K in modulating senile plaque formation has not yet
been investigated in depth. It is reported to enhance Aβ insertion into
the lipid bilayer, by decreasing intramolecular cohesive interactions
[37]. Moreover, it has been demonstrated that 7-K (125 uM) induces
mitochondrial dysfunction in the neuronal PC12 cell line, leading to cell
death, and also that incorporation of 7-K into lipid rafts domains of
plasma membranes triggers apoptotic signaling [38].
Interestingly, the correlation of tau pathology with 24-OH levels,
speciﬁcally with modulation of the enzyme CYP46A1, has been in-
vestigated by injecting the adeno-associated virus-CYP46A1 vector into
the hippocampus of THY-Tau22 mice; these animals are considered to
be a model of AD-like tau pathology. It was found that, in the hippo-
campus of these mice, levels of both 24-OH and CYP46A1 are lower
than in control mice. After injection of the vector, CYP46A1 and 24-OH
content were increased to control levels, and cognitive deﬁcits were
remedied, whereas tau hyperphosphorylation and associated gliosis
were unaﬀected, indicating that CYP46A1 may be a relevant ther-
apeutic target for tauopathies, and especially for AD [17]. Of note, very
recently, to test the eﬃcacy of reducing tau levels in the brain, anti-
sense oligonucleotides that selectively decrease tau mRNA and protein
have been identiﬁed in mice carrying human tau. Lowering total tau
expression was not only capable of preventing and reversing tau pa-
thology, but survival was signiﬁcantly extended and neuronal loss ab-
rogated, despite the fact that tau is an abundant and likely important
protein in the brain [39].
For these reasons it appears important to emphasize that the close
correlation among NFT formation, synaptic and neuronal failure, and
cognitive decline may underline the importance of identifying new
therapies targeting tau.
Recently, the connection between AD and sirtuins has received
much attention, and in particular it is now known that the deacetylase
SIRT1 takes part in neuroprotective pathways in AD, by exerting dif-
ferent beneﬁcial eﬀects: i) it is closely linked to inﬂammation, indeed it
regulates the anti-inﬂammatory response, by inhibiting the transcrip-
tion factor NF-κB through deacetylation of the Lys310 residue of RelA/
p65, and by activating the nuclear liver X receptor (LXR) via deacety-
lation of Lys432; ii) it activates the transcriptional co-activator peroxi-
some-proliferator-activated receptor γ co-activator 1α (PGC1α), which
plays a key role in the regulation of cellular energy metabolism and in
the antioxidant response; iii) its activation reduces Aβ plaques, thanks
to its ability to overexpress the α-secretase gene ADAM10; iiii) it pre-
vents NFT formation by deacetylating tau and inducing its degradation
[18,40].
Importantly, it has now been established that, in AD-aﬀected brains,
SIRT1 levels are markedly reduced, in parallel with the accumulation of
hyperphosphorylated tau [7,41]. In particular, previous results ob-
tained in the authors’ laboratory, on autopsy specimens from the cortex
of AD brains, classiﬁed by the Braak staging system of neuroﬁbrillary
pathology, have demonstrated that the expression levels of SIRT1 are
markedly reduced with the progression of AD, i.e. with the accumula-
tion of hyperphosphorylated tau [7].
Taking into account that, during AD progression, 24-OH and SIRT1
levels decrease on the one hand, and on the other hand NFT accumu-
lates, it appeared of interest to determine whether the loss of 24-OH
and SIRT1 could be responsible for the hyperphosphorylation of tau.
The aim of this study was to investigate in SK-N-BE cells the role in
tau pathology of two oxysterols present in AD brain, 24-OH and 7-K, in
particular concentrating on their ability to modulate tau phosphoryla-
tion, in some way aﬀecting the formation of NFT. This appears to be an
aspect that no studies have yet considered, since reported data relate
almost exclusively to the role of oxysterols in amyloid pathology.
Moreover, it was decided to study the potential ability of 24-OH and 7-
K to stimulate both expression and synthesis of SIRT1.
In this experimental model, 1 µM 24-OH has been proved to exert a
protective eﬀect on SK-N-BE cells, by upregulating both expression and
synthesis of SIRT1 (Fig. 1), consequently preventing the accumulation
of hyperphosphorylated tau, suggesting that 24-OH could be protective
against the aberrant formation of insoluble tau aggregates in neurons.
The reduced levels of phospho-tau following treatment with 24-OH
seems to be due to SIRT1-dependent deacetylation of tau (Fig. 3A).
Indeed, total tau levels were also signiﬁcantly reduced after cell treat-
ment with 24-OH (Fig. 3). It is hypothesized that 24-OH could con-
tribute to tau degradation by favoring SIRT1-dependent deacetylation
of tau; tau would thus become more susceptible to ubiquitination and
subsequent proteasomal degradation, leading to total tau reduction in
neurons [42]. Taking into account that the dysfunction of protein de-
gradation mechanisms has been proposed to play an important role in
AD [43,44], these results could represent the starting point for a new
tau-lowering therapy. Another explanation for the prevention of tau
hyperphosphorylation by 24-OH could be the potential ability of this
oxysterol to inhibit the activity of the kinases responsible for tau
phosphorylation, i.e. glycogen synthase kinase 3β (GSK3β), cyclin-de-
pendent kinase 5 (CDK5), protein kinase A (PKA), and microtubule
aﬃnity regulating kinase (MARK) [45]. Furthermore, in addition to the
reduced phosphorylation of tau, the increased tau dephosphorylation
could also be responsible for the eﬀect induced by 24-OH [46], together
with other post-translational modiﬁcations of tau, such as tau N-gly-
cosylation [47], or tau processing through proteolysis by caspases,
calpains, thrombin, and cathepsin [44]. Unlike 24-OH, 7-K did not
modulate SIRT1 levels in SK-N-BE cells (Fig. 2) and, as expected, it did
not aﬀect tau levels (Fig. 4).
The subsequent experiments were planned to verify whether a redox
imbalance might modulate the SIRT1-dependent axis favoring cell
survival. Indeed, although severe oxidative stress can be deleterious to
cells, moderate levels of ROS may function as signals to promote cell
proliferation and survival [48]. In the present study it was observed
that 24-OH, unlike 7-K, causes an early increase of ROS steady-state
levels in SK-N-BE cells (Fig. 5A). To conﬁrm the involvement of ROS
production in the 24-OH-dependent activation of SIRT1, and in the
consequent inhibition of hyperphosphorylated tau accumulation in
neurons, cells were incubated with apocynin or with rotenone. As ex-
pected, by blocking the intracellular generation of ROS, the protein
levels of SIRT1 were no longer upregulated (Fig. 5B) and, consequently,
tau phosphorylation levels rose (Fig. 5C). Further conﬁrmation of the
involvement of SIRT1 in the 24-OH-dependent neuroprotective eﬀects
was obtained by employing the gene silencing technique, through
which it was demonstrated that SIRT1 upregulation by 24-OH is ne-
cessary to prevent tau hyperphosphorylation (Fig. 5D).
Of note, tau phosphorylation is typically associated with a toxic
phenotype, as NFT are extensively hyperphosphorylated in human AD
brains and they are associated with neuronal death [49].
The neuroprotective action of 24-OH is strongly supported by in
vivo evidence obtained following the ICV injection of 24-OH or 7-K in
hTau mice that develop tau pathology only after Aβ monomer admin-
istration: 24-OH, unlike 7-K, induces SIRT1 protein levels and prevents
the phosphorylation of tau (Fig. 6).
The results reported here show, for the ﬁrst time, that the neuro-
protective eﬀect of 24-OH, in contrast to 7-K, is due to its ability to
increase levels and activity of SIRT1, which prevents tau phosphor-
ylation (Graphical abstract), although other molecular mechanisms
potentially involved in this eﬀect should be investigated.
5. Conclusion
Based on these results, it would clearly be of clinical importance to
prevent the loss of 24-OH in the brain by means of its administration, in
order to stimulate expression of SIRT1 in the long term with the con-
sequent prevention of NFT accumulation and tau pathology. These
ﬁndings thus oﬀer new avenues for the development of innovative
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prevention strategies for AD.
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